Biogen Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: BIIB Category:


Biogen has had one of its most eventful years so far in the history of the company. The company has seemingly made a major breakthrough in its neuroscience portfolio after the accelerated approval of Aduhelm, its medication for patients of the Alzheimer’s disease, on which the company’s future had been dependent for a very long time. The management believes that their recent accelerated approval could completely transform the treatment of Alzheimer’s disease but it has had its fair share of controversies so far with insurer reluctance and a review by the Congress. If the company surpasses these hurdles, it could be well-equipped for a long-term leadership in Alzheimer’s disease. Biogen’s product pipeline delivered meaningful mid-to-late-stage results in key areas, including depression, stroke, and biosimilars. Furthermore, Spinraza continued to perform very well outside the United States, with 23% revenue growth compared to the Q2 of last year. Given their recent growth trajectory, we give the stock a ‘Hold’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!